- Global Pharma News & Resources

Creative Biolabs Released A Comprehensive CAR Design & Construction Service

As a biopharmaceutical company highly specialized in cancer treatment R&D, Creative Biolabs recently has launched a brand new CAR design & construction service, aiming at clearing the tumor without the toxicity of conventional treatments.


CAR T therapy, a novel immunotherapy, is an excellent example of the application of basic research to the clinic. In detail, CAR stands for chimeric antigen receptor or artificial T cell receptor, which is engineered elaborately and endowing an immune effector cell (T cell) with an arbitrary specificity via a monoclonal antibody.



“There are four generations in the CAR design development history. The original CAR-T or the first-generation CAR consists of the intracellular domain from the CD3 ζ- chain and the primary transmitter of signals from endogenous TCRs. To augment the antitumor efficacy of 1st-generation CARs, the 2nd-generation were designed to combine the intracellular signaling domains from various costimulatory protein receptors. And the 3rd-generation of CARs combined multiple signaling domains (e.g., CD3 ζ-CD28-41BB, CD3 ζ-CD28-OX40) to acquire further enhanced function. ” A scientist from Creative Biolabs said that.


“The previous CAR strategies are highly specific and useful in redirecting T cells targeting malicious cancer cells. The 4th-generation CAR-T is designed to shape the tumor environment by the inducible release of transgenic immune modifiers, such as IL-12, which augments T-cell activation, attracts and activates innate immune cells to eliminate antigen-negative cancer cells in the targeted lesion.


With a professional team and advanced platforms, Creative Biolabs inherits advantages of CAR T strategy to help researchers make scientific history fighting malicious cancers.


About Creative Biolabs

As a global company, Creative Biolabs have more than 200 talented and well-trained scientists located in different continents working closely with partners from the entire world to develop and produce medicines of tomorrow. Specifically, we are the established leading expert in TCR and CAR T&NK cell immune therapy development, as we offer the one-stop custom services that cover the entire new drug development pipeline. Additionally, we also offer an exclusive line of ready-to-use TCR and CAR T&NK cell construction products, such as virus packaging, purification, expansion and titer determination kits. Furthermore, we have built up a unique unparalleled CAR construction and production platform for all four CAR generations.


Last Updated: 01-Aug-2019